adalimumab (D2E7)

BIOLOGICAL3 trials

Sponsors

Abbott

Conditions

Ankylosing SpondylitisCrohn's Disease

Phase 2

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

CompletedNCT00055523

AbbottCrohn's Disease

Start: 2002-04-30Target: 300Updated: 2006-08-15

Phase 3

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

CompletedNCT00085644

AbbottAnkylosing Spondylitis

Start: 2004-01-31End: 2009-07-31Updated: 2011-04-21

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

CompletedNCT00195819

AbbottAnkylosing Spondylitis

Start: 2003-12-31End: 2009-06-30Updated: 2011-06-28

Related Papers

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison

European Journal of Rheumatology2018-10-3014 citations

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab

Lara D. Veeken2014-12-2555 citations

Defining the Minimally Important Change for the SpondyloArthritis Research Consortium of Canada Spine and Sacroiliac Joint Magnetic Resonance Imaging Indices for Ankylosing Spondylitis.

2012-07-0130 citations

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

2012-06-1134 citations

Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.

2010-01-25173 citations

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.

2008-08-13121 citations

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.

2007-12-0438 citations